AnGes, Inc.
AnGes, Inc. is a pioneering biotechnology company dedicated to developing innovative gene-based pharmaceuticals and therapies. Since its founding in 1999, the company has focused on gene therapy products, nucleic acid medicines, and DNA vaccines, aiming to improve healthcare and quality of life through cutting-edge research and development. The company actively engages in clinical trials, regulatory approvals, and strategic collaborations worldwide, with a strong pipeline of products targeting various medical conditions including critical limb ischemia, premature aging syndromes, infectious diseases, and rare genetic diseases. The company also operates the AnGes Clinical Research Laboratory (ACRL), established in April 2021, which specializes in testing for rare genetic diseases and offers optional screening services. AnGes aims to become a global innovator in gene medicine, leveraging its extensive research, development, and licensing activities, including collaborations with universities and industry partners.
Industries
Nr. of Employees
medium (51-250)
Products
HGF plasmid gene therapy for ischemic vascular disease
Plasmid DNA therapy developed to induce angiogenesis and vascular regeneration for peripheral arterial disease and ischemic ulcers; advanced through clinical development with regulatory submissions, conditional/time-limited authorization and subsequent withdrawal of marketing application and sales.
NF-κB decoy oligonucleotide therapeutic for discogenic low back pain
Short decoy oligonucleotide designed to bind NF-κB transcription factors and suppress inflammatory gene expression; progressed through early clinical studies with published results and ongoing development into Phase II.
Plasmid DNA therapeutic vaccine for hypertension
Therapeutic DNA vaccine approach designed to elicit antibodies against angiotensin II to lower blood pressure; evaluated in early clinical studies.
Tie2 receptor agonist program for vascular stabilization (co-development)
Therapeutic program targeting vascular stabilization for acute respiratory and vascular dysfunction (e.g., ARDS); progressed into clinical evaluation under a co-development arrangement.
Commercialization and market access for externally developed orphan disease therapies
Regulatory submission, approval acquisition and domestic commercial launch activities for externally developed orphan disease therapies, integrated with diagnostic services and patient identification to support market access; includes executed approvals and launches for licensed products.
Lonafarnib for progeroid disorders (regulatory approval and launch)
Regulatory filing, approval and domestic commercialization of a farnesyltransferase inhibitor for progeria and related progeroid laminopathies; obtained manufacturing and marketing approval and subsequent market launch domestically.
HGF plasmid gene therapy for ischemic vascular disease
Plasmid DNA therapy developed to induce angiogenesis and vascular regeneration for peripheral arterial disease and ischemic ulcers; advanced through clinical development with regulatory submissions, conditional/time-limited authorization and subsequent withdrawal of marketing application and sales.
NF-κB decoy oligonucleotide therapeutic for discogenic low back pain
Short decoy oligonucleotide designed to bind NF-κB transcription factors and suppress inflammatory gene expression; progressed through early clinical studies with published results and ongoing development into Phase II.
Plasmid DNA therapeutic vaccine for hypertension
Therapeutic DNA vaccine approach designed to elicit antibodies against angiotensin II to lower blood pressure; evaluated in early clinical studies.
Tie2 receptor agonist program for vascular stabilization (co-development)
Therapeutic program targeting vascular stabilization for acute respiratory and vascular dysfunction (e.g., ARDS); progressed into clinical evaluation under a co-development arrangement.
Commercialization and market access for externally developed orphan disease therapies
Regulatory submission, approval acquisition and domestic commercial launch activities for externally developed orphan disease therapies, integrated with diagnostic services and patient identification to support market access; includes executed approvals and launches for licensed products.
Lonafarnib for progeroid disorders (regulatory approval and launch)
Regulatory filing, approval and domestic commercialization of a farnesyltransferase inhibitor for progeria and related progeroid laminopathies; obtained manufacturing and marketing approval and subsequent market launch domestically.
Services
Centralized expanded newborn and rare genetic disease screening
Registered central laboratory service offering expanded newborn and rare genetic disease screening panels, including sample receipt, genetic and biomarker assay processing and clinical reporting for hospitals, municipalities and other ordering organizations.
Contract genetic and biomarker testing to support clinical programs
Contract laboratory services providing genetic and biomarker assays to support clinical trial enrollment, patient stratification and companion diagnostic workflows for sponsors and research collaborators.
Sponsored research and collaborative R&D programs
Management and execution of sponsored research agreements and collaborative projects with academic institutions and industry partners for translational research, formulation development and genome-edited therapeutic discovery.
Centralized expanded newborn and rare genetic disease screening
Registered central laboratory service offering expanded newborn and rare genetic disease screening panels, including sample receipt, genetic and biomarker assay processing and clinical reporting for hospitals, municipalities and other ordering organizations.
Contract genetic and biomarker testing to support clinical programs
Contract laboratory services providing genetic and biomarker assays to support clinical trial enrollment, patient stratification and companion diagnostic workflows for sponsors and research collaborators.
Sponsored research and collaborative R&D programs
Management and execution of sponsored research agreements and collaborative projects with academic institutions and industry partners for translational research, formulation development and genome-edited therapeutic discovery.
Expertise Areas
- Plasmid DNA therapeutics development and CMC
- Nucleic acid therapeutics design and clinical development
- Genome-editing platform development and integration
- DNA vaccine platforms and mucosal (intranasal) delivery
Key Technologies
- Plasmid DNA production and formulation
- Oligonucleotide therapeutics (decoy, siRNA)
- Nuclease-based genome editing platforms
- DNA vaccine platforms and intranasal delivery systems